J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0091270007310386v1
48/3/330    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ohno, T.
Right arrow Articles by Ohnishi, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohno, T.
Right arrow Articles by Ohnishi, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

DRUG INTERACTIONS

Effect of Itraconazole on the Pharmacokinetics of Imidafenacin in Healthy Subjects

Tomoya Ohno, MS, Kazuki Nakayama, MS, Susumu Nakade, PhD, Junsaku Kitagawa, MS, Shinya Ueda, PhD, Hiroyuki Miyabe, MS, Yasuyuki Miyata, MS and Akihiro Ohnishi, MD, PhD

From the Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co, Ltd, Ibaraki, Japan (Mr Ohno, Mr Nakayama, Dr Nakade, Mr Kitagawa, Dr Ueda, Mr Miyabe, Mr Miyata) and Department of Laboratory Medicine, Daisan Hospital, Jikei University School of Medicine, Tokyo, Japan (Dr Ohnishi).

The effect of itraconazole, a potent inhibitor of the CYP3A isoenzyme family, on the pharmacokinetics of imidafenacin, a novel synthetic muscarinic receptor antagonist, was investigated. Twelve healthy subjects participated in this open-label, self-controlled study. In period I, subjects received a single oral dose of 0.1 mg imidafenacin. In period II, they received multiple oral doses of 200 mg itraconazole for 9 days and a single oral dose of 0.1 mg imidafenacin on day 8. Plasma concentrations of imidafenacin and M-2, the major metabolite of imidafenacin metabolized by CYP3A4, were determined. Analytes were measured by liquid chromatography tandem mass spectrometry. Following coadministration with itraconazole, the maximum plasma concentration (Cmax) of imidafenacin increased 1.32-fold (90% confidence intervals [CIs]: 1.12-1.56), and the area under the plasma concentration-time curve from time 0 to infinity (AUC0-{infty}) increased 1.78-fold (90% CI: 1.47-2.16). In conclusion, itraconazole increases the plasma concentrations of imidafenacin by inhibiting CYP3A4. Therefore, itraconazole or potent CYP3A4 inhibitors should be carefully added to imidafenacin drug regimens.

Key Words: Imidafenacin • drug-drug interaction • pharmacokinetics • itraconazole • human

Address for correspondence: Tomoya Ohno, Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co, Ltd, 17-2 Wadai Tsukuba, Ibaraki 300-4247 Japan; e-mail: to.ohno{at}ono.co.jp.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American College of Clinical Pharmacology